First Tracks Biotherapeutics, Inc. SEC filings TRAX

First Tracks Biotherapeutics, Inc. has 98 filings in SEC EDGAR's recent list, going back to Feb 6, 2026. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.

First Tracks Biotherapeutics, Inc. SEC filings
Form Description Filed Period
424B3 Prospectus Nov 4, 2026 —
424B3 Prospectus Nov 4, 2026 —
4 Insider transaction Nov 3, 2026 Nov 1, 2026
4 Insider transaction Nov 3, 2026 Nov 1, 2026
4 Insider transaction Nov 3, 2026 Nov 1, 2026
4 Insider transaction Nov 3, 2026 Nov 1, 2026
10-Q Quarterly report Nov 3, 2026 Sep 30, 2026
8-K Current report
Results of operations
Nov 3, 2026 Nov 3, 2026
EFFECT Filing Oct 29, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Oct 27, 2026 —
S-1 Registration statement Oct 26, 2026 —
8-K Current report
Material agreement
Oct 20, 2026 Oct 19, 2026
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Oct 15, 2026 Oct 15, 2026
8-K Current report
Regulation FD disclosure, Other events
Oct 13, 2026 Oct 12, 2026
4 Insider transaction Sep 17, 2026 Sep 15, 2026
4 Insider transaction Sep 4, 2026 Sep 2, 2026
144 Notice of proposed sale Sep 2, 2026 —
4 Insider transaction Aug 18, 2026 Aug 15, 2026
4 Insider transaction Aug 18, 2026 Aug 15, 2026
4 Insider transaction Aug 18, 2026 Aug 15, 2026
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 13, 2026 —
424B3 Prospectus Aug 13, 2026 —
10-Q Quarterly report Aug 12, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 12, 2026 Aug 12, 2026
3/A Filing Aug 7, 2026 Apr 20, 2026
3/A Filing Aug 7, 2026 Apr 20, 2026
3/A Filing Aug 7, 2026 Apr 20, 2026
SCHEDULE 13G Ownership over 5% (passive) Aug 6, 2026 —
4 Insider transaction Aug 5, 2026 Aug 2, 2026
4 Insider transaction Aug 5, 2026 Aug 2, 2026
4 Insider transaction Aug 5, 2026 Aug 2, 2026
SCHEDULE 13G Ownership over 5% (passive) Jul 28, 2026 —
8-K Current report
Material agreement
Jun 22, 2026 Jun 15, 2026
4 Insider transaction Jun 17, 2026 Jun 15, 2026
4 Insider transaction Jun 17, 2026 Jun 15, 2026
4 Insider transaction Jun 17, 2026 Jun 15, 2026
4 Insider transaction Jun 17, 2026 Jun 15, 2026
4 Insider transaction Jun 17, 2026 Jun 15, 2026
4 Insider transaction Jun 17, 2026 Jun 15, 2026
4/A Filing Jun 12, 2026 May 12, 2026
4/A Filing Jun 12, 2026 May 12, 2026
4/A Filing Jun 12, 2026 May 12, 2026
4/A Filing Jun 12, 2026 May 12, 2026
4/A Filing Jun 12, 2026 May 12, 2026
4/A Filing Jun 12, 2026 May 12, 2026
424B3 Prospectus May 15, 2026 —
424B3 Prospectus May 14, 2026 —
10-Q Quarterly report May 14, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 14, 2026 May 14, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
4 Insider transaction May 14, 2026 May 12, 2026
EFFECT Filing May 12, 2026 —
CORRESP Letter to the SEC May 8, 2026 —
S-1 Registration statement May 8, 2026 —
UPLOAD Letter from the SEC May 6, 2026 —
DRS Filing May 1, 2026 —
4 Insider transaction Apr 23, 2026 Apr 21, 2026
3 Initial insider ownership Apr 23, 2026 Apr 17, 2026
SCHEDULE 13G Ownership over 5% (passive) Apr 22, 2026 —
4 Insider transaction Apr 22, 2026 Apr 20, 2026
3 Initial insider ownership Apr 22, 2026 Apr 20, 2026
3 Initial insider ownership Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
4 Insider transaction Apr 22, 2026 Apr 20, 2026
8-K Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Other events
Apr 20, 2026 Apr 20, 2026
S-8 Employee stock plan registration Apr 17, 2026 —
8-K Current report
Regulation FD disclosure
Apr 3, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
3 Initial insider ownership Apr 1, 2026 Apr 1, 2026
SEC STAFF ACTION Filing Apr 1, 2026 —
CERT Filing Apr 1, 2026 —
10-12B/A Filing Mar 27, 2026 —
10-12B Filing Mar 3, 2026 —
DRS Filing Feb 6, 2026 —

Showing 98 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TRAX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2091349
Former names
Biopharma Company, Inc. (until Feb 6, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.